These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38889002)

  • 1. Separation of Activated T Cells Using Multidimensional Double Spiral (MDDS) Inertial Microfluidics for High-Efficiency CAR T Cell Manufacturing.
    Jeon H; Perez CR; Kyung T; Birnbaum ME; Han J
    Anal Chem; 2024 Jul; 96(26):10780-10790. PubMed ID: 38889002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a microfluidic cell transfection device into gene-edited CAR T cell manufacturing workflow.
    Yu T; Jhita N; Shankles P; Fedanov A; Kramer N; Raikar SS; Sulchek T
    Lab Chip; 2023 Nov; 23(22):4804-4820. PubMed ID: 37830228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomaterials in Chimeric Antigen Receptor T-Cell Process Development.
    Cardle II; Cheng EL; Jensen MC; Pun SH
    Acc Chem Res; 2020 Sep; 53(9):1724-1738. PubMed ID: 32786336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inertial Microfluidic Purification of CAR-T-Cell Products.
    Elsemary MT; Maritz MF; Smith LE; Warkiani M; Bandara V; Napoli S; Barry SC; Coombs JT; Thierry B
    Adv Biol (Weinh); 2022 Jan; 6(1):e2101018. PubMed ID: 34881810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended characterization of anti-CD19 CAR T cell products manufactured at the point of care using the CliniMACS Prodigy system: comparison of donor sources and process duration.
    Malakhova E; Pershin D; Kulakovskaya E; Vedmedskaia V; Fadeeva M; Lodoeva O; Sozonova T; Muzalevskii Y; Kazachenok A; Belchikov V; Shelikhova L; Molostova O; Volkov D; Maschan M
    Cytotherapy; 2024 Jun; 26(6):567-578. PubMed ID: 38493403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deterministic Lateral Displacement: The Next-Generation CAR T-Cell Processing?
    Campos-González R; Skelley AM; Gandhi K; Inglis DW; Sturm JC; Civin CI; Ward T
    SLAS Technol; 2018 Aug; 23(4):338-351. PubMed ID: 29361868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic CAR T cell purification using an anti-G4S linker antibody.
    Harrer DC; Li SS; Kaljanac M; Bezler V; Barden M; Pan H; Herr W; Abken H
    J Immunol Methods; 2024 May; 528():113667. PubMed ID: 38574803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new approach to CAR T-cell gene engineering and cultivation using piggyBac transposon in the presence of IL-4, IL-7 and IL-21.
    Ptáčková P; Musil J; Štach M; Lesný P; Němečková Š; Král V; Fábry M; Otáhal P
    Cytotherapy; 2018 Apr; 20(4):507-520. PubMed ID: 29475789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
    Gargett T; Truong N; Ebert LM; Yu W; Brown MP
    Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enrichment of T-lymphocytes from leukemic blood using inertial microfluidics toward improved chimeric antigen receptor-T cell manufacturing.
    Elsemary MT; Maritz MF; Smith LE; Warkiani ME; Thierry B
    Cytotherapy; 2024 Oct; 26(10):1264-1274. PubMed ID: 38819362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approaches of T Cell Activation and Differentiation for CAR-T Cell Therapies.
    Schwab RD; Bedoya DM; King TR; Levine BL; Posey AD
    Methods Mol Biol; 2020; 2086():203-211. PubMed ID: 31707678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
    Ghassemi S; Milone MC
    J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A quality-by-design approach to improve process understanding and optimise the production and quality of CAR-T cells in automated stirred-tank bioreactors.
    Hood T; Slingsby F; Sandner V; Geis W; Schmidberger T; Bevan N; Vicard Q; Hengst J; Springuel P; Dianat N; Rafiq QA
    Front Immunol; 2024; 15():1335932. PubMed ID: 38655265
    [No Abstract]   [Full Text] [Related]  

  • 15. Expanding CAR-T cell immunotherapy horizons through microfluidics.
    Kim H; Kim S; Lim H; Chung AJ
    Lab Chip; 2024 Feb; 24(5):1088-1120. PubMed ID: 38174732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR-T cell expansion platforms yield distinct T cell differentiation states.
    Song HW; Prochazkova M; Shao L; Traynor R; Underwood S; Black M; Fellowes V; Shi R; Pouzolles M; Chou HC; Cheuk AT; Taylor N; Jin P; Somerville RP; Stroncek DF; Khan J; Highfill SL
    Cytotherapy; 2024 Jul; 26(7):757-768. PubMed ID: 38625071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells.
    Wang L; Gong W; Wang S; Neuber B; Sellner L; Schubert ML; Hückelhoven-Krauss A; Kunz A; Gern U; Michels B; Hinkelbein M; Mechler S; Richter P; Müller-Tidow C; Schmitt M; Schmitt A
    Cytotherapy; 2019 May; 21(5):566-578. PubMed ID: 30910382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD81 costimulation skews CAR transduction toward naive T cells.
    Schultz LM; Czerwinski DK; Levy R; Levy S
    Proc Natl Acad Sci U S A; 2022 Feb; 119(5):. PubMed ID: 35091467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
    Teoh J; Brown LF
    Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steering CAR T cell epigenetic programs by tweaking manufacturing protocol.
    Dukes MW; Krenciute G
    Cell Rep Med; 2023 Jun; 4(6):101080. PubMed ID: 37343521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.